Literature DB >> 25819159

Feasibility of a subcutaneously administered block/homo-mixed polyplex micelle as a carrier for DNA vaccination in a mouse tumor model.

Lin Cui1, Kensuke Osada2, Akira Imaizumi1, Kazunori Kataoka3, Kenji Nakano4.   

Abstract

In this study, the potential of DNA vaccine by subcutaneously (s.c.) administered block/homo-mixed (B/H) polyplex micelles carrying genes encoding tumor-associated antigen SART3 as well as CD40L and GM-CSF was compared with the intraperitoneal (i.p.) and intravenous (i.v.) administrations or electroporation method. Confocal laser microscopy revealed high localization of polyplexes in groin lymph nodes and local skin tissues after s.c. administration, and in the mesenteric lymph nodes, liver, and spleen after i.p. administration, but not after i.v. administration. Real-time RT-PCR and immunohistochemistry showed transgene expression in the above organs by s.c. and i.p. administered B/H polyplex micelles, but not by the i.v. administration or electroporation. Polyplex-carried DNA vaccines significantly decreased the weight of subcutaneous CT26 tumors in mice compared to the mock (2.9±0.8 vs 6.4±2.6 g, P<0.05 for s.c.; 3.2±1.1 vs 4.7±2.1 g, P<0.05 for i.p. administration). The survival rate was improved by s.c. administration of the DNA vaccine (P<0.05) and by the i.p. administered DNA vaccine (P<0.01) compared with that of the mock controls in mice with peritoneally disseminated CT26 cancer. Such therapeutic effects were not observed by the naked DNA, i.v. administered DNA vaccine or electroporation. CTL and NK cell activities of splenocytes and infiltration of CD11c(+) DCs, and CD4(+) and CD8a(+) T cells into tumor tissues were upregulated in the s.c. administered DNA vaccine group (P<0.05), which was consistent with i.p. administration. No abnormal findings in local injection sites, body weight, or blood examinations were observed by s.c. or i.p. administration of polyplex micelles, whereas proinflammatory cytokine production was minimized in visceral organs with the s.c. administered polyplex-carried DNA vaccine. In conclusion, s.c. administration of B/H polyplex micelles may be a safe and useful modality for DNA vaccination.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CTL; DNA vaccine; Polyplex micelle; Subcutaneous administration; Tumor rejection immunity

Mesh:

Substances:

Year:  2015        PMID: 25819159     DOI: 10.1016/j.jconrel.2015.03.029

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

Review 1.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

Review 2.  Advances in the polymeric delivery of nucleic acid vaccines.

Authors:  Gang Chen; Bowen Zhao; Elena F Ruiz; Fuwu Zhang
Journal:  Theranostics       Date:  2022-05-13       Impact factor: 11.600

3.  Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines.

Authors:  Feng Qiu; Kyle W Becker; Frances C Knight; Jessalyn J Baljon; Sema Sevimli; Daniel Shae; Pavlo Gilchuk; Sebastian Joyce; John T Wilson
Journal:  Biomaterials       Date:  2018-07-30       Impact factor: 12.479

Review 4.  Micelle-Based Adjuvants for Subunit Vaccine Delivery.

Authors:  Thomas Trimaille; Bernard Verrier
Journal:  Vaccines (Basel)       Date:  2015-09-25

Review 5.  Advanced biomaterials for cancer immunotherapy.

Authors:  Fan Yang; Kun Shi; Yan-Peng Jia; Ying Hao; Jin-Rong Peng; Zhi-Yong Qian
Journal:  Acta Pharmacol Sin       Date:  2020-03-02       Impact factor: 6.150

Review 6.  Polymeric Micelles in Cancer Immunotherapy.

Authors:  Zhuoya Wan; Ruohui Zheng; Pearl Moharil; Yuzhe Liu; Jing Chen; Runzi Sun; Xu Song; Qiang Ao
Journal:  Molecules       Date:  2021-02-25       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.